Re-escalation of anti-TNF therapy is common among older adults with RA and typically occurs within 6 months of prior de-escalation.
TNF is a central regulator of immune responses, inflammation and programmed cell death, and has an essential role in maintaining tissue and immune homeostasis. Abnormal TNF signalling is implicated in ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results